反 舞 弊 制 度 贵州三力制药股份有限公司 反舞弊制度 第一章 总则 第一条 为防治舞弊，加强贵州三力制药股份有限公司（以下简称"公司"）的公司治理和内部控制， 维护公司和股东合法权益，根据《公司法》《企业内部控制基本规范》及《公司章程》的有关规定，结合 公司实际情况，特制定本制度。 第二条 本制度所指舞弊行为，是指公司内、外人员采用欺骗等违法、违规手段，谋取个人不正当利 益，损害公司正当经济利益的行为；或谋取不当的公司经济利益，同时可能为个人带来不正当利益的行为。 舞弊包括损害公司正当经济利益的舞弊和谋取不当的公司经济利益的舞弊。 第三条 公司反舞弊工作的宗旨是规范公司中高级管理人员及所有员工的职业行为，防止损害公司及 股东利益的行为发生。 第四条 公司反舞弊内控机制，包括设立举报投诉渠道以防范和发现舞弊行为，实施控制措施以降低 舞弊发生的机会，对舞弊行为带来的危害采取适当且有效的补救措施。 第五条 本制度适用于公司、分公司、控股子公司及重要参股子公司。 第二章 舞弊行为及反舞弊职责归属 第六条 有下列情形之一者属于舞弊行为： （一）收受、索取贿赂或回扣，特别是招标及采购过程中存在暗箱操作等行为，员工或其 ...

现就2024年度履职情况报告如下： 一、独立董事的基本情况 贵州三力制药股份有限公司 独立董事年度述职报告 （归东） 根据中国证监会《上海证券交易所股票上市规则》《上市公司治 理准则》《上市公司独立董事管理办法》和《贵州三力制药股份有限 公司公司章程》（以下简称"《公司章程》"）等有关规定，作为贵 州三力制药股份有限公司（以下简称"公司"）独立董事，本人勤勉 尽责地履行独立董事职责。通过积极参与董事会及各专门委员会会议， 深入调研公司主营业务发展状况，重点关注行业转型升级过程中的战 略规划、风险管控及公司治理等重点事项。在履职过程中，本人始终 保持独立判断，对重大经营决策、财务报告、内部控制等事项进行审 慎核查并提出专业意见，切实维护公司及全体股东特别是中小股东的 合法权益。 2024年度，公司共召开董事会11次，股东大会3次，本人参与的 董事会、股东大会情况如下： 本人归东：男，中国国籍，1974年2月生，西南政法大学法学学 士，湘潭大学法律硕士。1996年至2003年就职于贵州省社会科学院法 学研究所；1999年至2003年以兼职律师身份先后在贵州公达律师事务 所和贵州晨吉律师事务所执业；2003年12月 ...

第三条 公司内部审计遵循"独立、客观、公正、保密"原则。 第四条 公司董事会对内部控制制度的建立健全和有效实施负责，重要的内部控制制度应当经董事会审议 通过。公司董事会及其全体成员保证内部控制相关信息披露内容的真实、准确、完整。 第五条 公司各部门、各子公司应当配合内部审计机构依法履行职责，提供必要的工作条件，不得妨碍内 部审计机构的工作。 内部审计制度 贵州三力制药股份有限公司 内部审计制度 第一章 总则 第一条 为规范贵州三力制药股份有限公司（以下简称"公司"）内部审计工作，提高内部审计工作质量， 保护投资者合法权益，根据《中华人民共和国审计法》《审计署关于内部审计工作的规定》等法律法规、规章 和《上海证券交易所股票上市规则》《上海证券交易所上市公司自律监管指引第 1 号——规范运作》《贵州三 力股份有限公司章程》（以下简称"《公司章程》"）的规定并结合公司实际，制定本制度。 第二条 本制度所称内部审计工作，是指公司内部审计机构或人员，对公司内部控制和风险管理的有效性、 财务信息的真实性和完整性以及经营活动的效率和效果等开展的一种评价活动。 第十条 审计人员开展内部审计工作应保持独立性，坚持客观公正、实事 ...

贵州三力制药股份有限公司 独立董事年度述职报告 （冯卫生） 根据中国证监会《上海证券交易所股票上市规则》《上市公司治 理准则》《上市公司独立董事管理办法》和《贵州三力制药股份有限 公司公司章程》（以下简称"《公司章程》"）等有关规定，作为贵 州三力制药股份有限公司（以下简称"公司"）独立董事，本人在2024 年任职期间，本着对公司和股东负责的态度，忠实、勤勉、尽责地履 行独立董事职责。 现就2024年度履职情况报告如下： 一、独立董事的基本情况 本人冯卫生：男，中国国籍，1960年9月生，博士研究生学历， 日本冈山大学药学客座研究员。2008年至今，历任河南中医药大学药 学院院长、副校长、二级教授。2011年至2015年期间，任河南羚锐制 药股份有限公司独立董事。2024年10月至今，任公司独立董事。 作为公司独立董事，本人及直系亲属、主要社会关系没有在公司 及其附属企业任职，也没有在直接或间接持有公司5%或5%以上已发行 股份的股东单位任职；没有为公司及其附属企业提供财务、法律、管 理咨询、技术咨询等有偿服务，也没有从公司及其主要股东单位或有 利害关系的机构取得未予披露的其他利益，不存在影响独立性的情况。 ...

Financial Performance - The audited net profit attributable to shareholders for 2024 is CNY 274,027,809.74, with the parent company's distributable profit at CNY 795,682,511.91[7]. - The proposed cash dividend for 2024 is CNY 3.40 per 10 shares (including tax), with no bonus shares or capital reserve conversion[7]. - The company achieved a revenue of approximately CNY 2.14 billion in 2024, representing a year-on-year increase of 31.16%[25]. - The net profit attributable to shareholders decreased by 6.38% to approximately CNY 274 million in 2024[25]. - The net profit attributable to shareholders after deducting non-recurring gains and losses increased by 9.08% to approximately CNY 268 million[25]. - The net cash flow from operating activities decreased by 61.30% to approximately CNY 107 million, primarily due to increased tax payments and employee compensation[26]. - The company's total assets increased by 9.30% to approximately CNY 3.19 billion at the end of 2024[25]. - The company’s equity attributable to shareholders increased by 3.88% to approximately CNY 1.53 billion at the end of 2024[25]. - The company reported an operating revenue of CNY 2,144.39 million for the year 2024, marking a year-on-year growth of 31.16%[74]. Risk Management - The report includes a risk statement regarding forward-looking statements, indicating potential challenges and risks that may affect future development[8]. - The company emphasizes the importance of considering industry development trends and operational conditions when making profit distribution decisions[7]. - The company’s management discussion highlights potential risks and challenges in future operations, which do not constitute a commitment to investors[10]. - The company has not reported any non-operating fund occupation by controlling shareholders or related parties[9]. - There are no violations of decision-making procedures for external guarantees reported[9]. Operational Developments - The company established a nationwide OTC direct sales network, adding 13 provincial branches and a professional marketing team of over 1,700 members[36]. - The revenue from the OTC channel significantly increased, surpassing that of the prescription channel, enhancing the company's resilience to policy risks[36]. - The company plans to invest in the biopharmaceutical sector as part of its strategic layout for future growth[36]. - In 2024, the company expanded its OTC channel coverage by adding 27 major chain pharmacies and over 800 small chain pharmacies, achieving a multi-layered terminal system with over 60,000 third-party terminals[37]. - The company established deep partnerships with major e-commerce platforms like JD Health and Alibaba Health, resulting in significant growth in online sales revenue through data-driven product selection and marketing[38]. Research and Development - The company initiated 11 new R&D projects for core products, with 3 projects making significant progress, and published 11 academic papers to support prescription channel sales[39]. - The smart factory completed its construction by April 2024, enhancing production quality and efficiency through standardized, automated, and intelligent processes[40]. - The company implemented a data-driven management system, improving decision-making speed and accuracy through real-time operational data updates and integrated data governance[42]. - The company’s R&D investment amounted to RMB 2,313.92 million, representing 1.06% of operating revenue, with a year-on-year increase of 2.28%[110]. - The company’s investment in core product re-evaluation research totaled RMB 937.33 million, contributing to ongoing product development efforts[110]. Market Trends and Industry Insights - The pharmaceutical manufacturing industry in China saw a 3.4% year-on-year increase in value added, reversing a previous decline of 5.2%[48]. - The population aged 65 and above reached 220 million in 2024, driving demand for chronic disease treatment and health management, thus stabilizing drug consumption[49]. - The pharmaceutical manufacturing industry is experiencing resilient growth driven by innovation, digital transformation, and internationalization strategies despite challenges such as shrinking profit margins[50]. - The overall policy direction emphasizes "innovation-driven, structural optimization, and compliance upgrading" to facilitate high-quality industry development[59]. - The focus on digital transformation in traditional Chinese medicine aims to integrate big data and AI technologies over the next 3-5 years, enhancing the industry's modernization[55]. Governance and Compliance - The company’s governance structure includes a clear division of responsibilities among the shareholders' meeting, board of directors, and supervisory board, ensuring compliance with legal regulations[138]. - The company has held three shareholders' meetings in 2024, all of which complied with legal and procedural requirements[140]. - The company has established a comprehensive internal control system, enhancing management effectiveness and risk control[175]. - The internal control audit report for 2024 received a standard unqualified opinion from the auditing firm[177]. - The company has not faced any penalties from securities regulatory authorities in the past three years[151]. Environmental Responsibility - The company has invested 1,480,500 RMB in environmental protection during the reporting period[179]. - Guizhou Sanli Pharmaceutical Co., Ltd. has established a wastewater treatment plant with a capacity of 400 tons per day, achieving COD and ammonia nitrogen removal rates exceeding 98%[183]. - Guizhou Hanfang Pharmaceutical Co., Ltd. has a wastewater treatment plant with a capacity of 800 tons per day, achieving COD and ammonia nitrogen removal rates above 98%[185]. - The company remains compliant with pollution discharge standards, with all monitored pollutants meeting regulatory requirements[181]. - The company has implemented a comprehensive environmental monitoring strategy to ensure compliance with regulatory standards[196]. Employee Engagement and Compensation - The total number of employees in the parent company is 2,091, with a total of 2,852 employees across the parent and major subsidiaries[159]. - The company has established a performance-based compensation system linked to job value and contribution, aiming to enhance employee motivation[160]. - The total remuneration for all directors, supervisors, and senior management during the reporting period amounted to 694.11 million yuan[148]. - The company has conducted 283 training sessions during the reporting period to enhance employee skills and strengthen corporate culture[161]. - The company has adjusted its cash dividend policy for the years 2024-2026, which was approved in a recent shareholders' meeting[162].

Financial Performance - The company's operating revenue for Q1 2025 was CNY 408,589,489.70, a decrease of 3.18% compared to CNY 422,024,144.62 in the same period last year[4] - Net profit attributable to shareholders was CNY 41,946,770.84, down 25.16% from CNY 56,048,131.61 year-on-year[4] - The net profit after deducting non-recurring gains and losses was CNY 38,582,237.18, reflecting a decline of 31.56% compared to CNY 56,375,781.05 in the previous year[4] - Operating profit for Q1 2025 was CNY 47,244,699.17, down 31.6% from CNY 69,106,865.79 in Q1 2024[17] - The net profit for Q1 2025 was CNY 42,536,659.52, a decrease of 25.2% compared to CNY 56,860,529.64 in Q1 2024[18] - The company’s total comprehensive income for Q1 2025 was CNY 42,536,659.52, down from CNY 56,860,529.64 in Q1 2024, a decrease of 25.2%[18] Cash Flow - The net cash flow from operating activities was negative CNY 15,082,051.92, a significant decrease of 346.95% from CNY 6,107,280.58 in the same period last year[4] - Cash flow from operating activities for Q1 2025 was negative at CNY -15,082,051.92, compared to a positive CNY 6,107,280.58 in Q1 2024[22] - Total cash inflow from operating activities in Q1 2025 was CNY 455,154,437.28, slightly down from CNY 464,880,944.73 in Q1 2024[22] - Cash outflow from operating activities increased to CNY 470,236,489.20 in Q1 2025, compared to CNY 458,773,664.15 in Q1 2024, marking an increase of 2.5%[22] - The net cash flow from investing activities was CNY -209,654,656.82 in Q1 2025, significantly worse than CNY -10,385,541.40 in Q1 2024[23] - Cash inflow from financing activities in Q1 2025 was CNY 119,156,787.76, compared to CNY 24,200,000.00 in Q1 2024, indicating a substantial increase[23] Assets and Liabilities - Total assets at the end of the reporting period were CNY 3,144,369,139.65, a decrease of 1.50% from CNY 3,192,107,890.63 at the end of the previous year[5] - Total liabilities amounted to CNY 1,503,503,195.92, a decrease from CNY 1,597,480,848.71[14] - Total equity attributable to shareholders was CNY 1,572,831,702.50, an increase from CNY 1,527,340,401.45[14] - Cash and cash equivalents decreased to CNY 55,335,081.52 from CNY 22,945,081.52[12] - Accounts receivable increased to CNY 769,390,951.04 from CNY 728,669,788.22[12] - Inventory increased to CNY 347,636,773.07 from CNY 320,722,064.52[12] Shareholder Information - Basic and diluted earnings per share were both CNY 0.10, down 28.57% from CNY 0.14 in the previous year[4] - The company reported an increase in the number of ordinary shareholders to 26,433 by the end of the reporting period[8] - Basic and diluted earnings per share for Q1 2025 were both CNY 0.10, down from CNY 0.14 in Q1 2024, representing a decline of 28.6%[18] Costs and Expenses - Total operating costs for Q1 2025 were CNY 360,500,086.77, an increase of 1.0% from CNY 354,161,051.46 in Q1 2024[17] - Research and development expenses for Q1 2025 were CNY 7,416,057.12, a decrease of 16.5% compared to CNY 8,891,832.83 in Q1 2024[17] - The decline in net profit attributable to shareholders was mainly due to rising material costs[6] Non-Recurring Items - Non-recurring gains and losses totaled CNY 3,364,533.66, primarily due to government subsidies and other income[6]

贵州三力制药股份有限公司 2025 年度财务预算报告 贵州三力制药股份有限公司（以下简称"公司"）2025 年度财务预算报告 编制工作已经完成。本预算报告遵循谨慎性原则，在公司中长期发展战略框架内， 综合 2025 年宏观经济预期与企业产品需求预期，目前生产排产计划、新业务拓 展计划等因素，在公司预算基础上，按合并报表的要求进行编制。 现受董事会委托，向本次会议作 2025 年度财务预算报告，请予以审议。 一、预算工作安排情况 2025 年公司财务预算是根据公司以前年度的实际经营情况、财务状况和经 营成果，结合公司目前具备的各项现实基础、经营能力以及年度经营计划，本着 坚持战略引领，注重价值导向，稳健发展的原则编制而成。 公司根据上年实际情况，认真研判 2025 年度经济形势及市场行情，结合国 内外经济环境及行业运行特点认真分析研究了 2025 年公司发展面临的机遇与挑 战，明确预算落实的思路、措施及策略，对本年度销售计划、采购计划、生产计 划进行了安排、部署及汇总。 二、预算编制的基本假设 1、公司遵循的法律、行政法规、政策及经济环境不发生重大变化: 2、公司所处行业形势、市场需求无重大变化; 3、现行主要 ...

证券代码：603439 证券简称：贵州三力 公告编号：2025-020 为满足公司及子公司经营发展需要，提高资金运营能力，现根据实际生产经 营发展需要和总体发展规划，公司及合并报表范围内子公司拟向银行申请不超过 人民币 15 亿元的综合授信额度，期限为自 2024 年年度股东大会审议通过之日起 至 2025 年年度股东大会召开之日。上述授信额度不等于公司实际融资金额，实 际授信额度最终以银行最后审批的授信额度为准，具体融资金额将视公司运营资 金的实际需求来确定。在授信期限内，授信额度可循环使用。 为提高工作效率，及时办理融资业务，董事会提请股东大会授权公司董事长 及其授权代表根据实际经营情况的需要，在上述授信额度内代表公司办理相关业 务，并签署有关法律文件。根据《上海证券交易所股票上市规则（2024 年 4 月 修订）》和《公司章程》等相关规定，本次申请综合授信事项需提交公司 2024 年年度股东大会审议通过。 特此公告。 贵州三力制药股份有限公司董事会 2025年4月23日 1 贵州三力制药股份有限公司 关于 2025 年度公司及控股子公司 向银行申请综合授信额度的公告 本公司董事会及全体董事保证本公告内容 ...

贵州三力制药股份有限公司 关于2024年度日常关联交易情况及 2025年度日常关联交易预计的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实、准确和完整承担法律责任。 重要内容提示： 本事项无需提交股东大会审议 日常关联交易对上市公司的影响：贵州三力制药股份有限公司（以下简 称"贵州三力"或"公司"）2024年度日常关联交易所涉及业务全部为正常的经 营性往来，关联交易价格严格遵守了公开、公平、公正及市场化定价的原则，公 司未对关联方形成较大依赖。 证券代码：603439 证券简称：贵州三力 公告编号：2024-017 （单位：万元） | 关联交易 类别 | 关联人 | 2025年度 预计金额 | 占同类业 务比例 （%） | 本年年初至披露日 与关联人累计已发 生的交易金额 | 2024年度实际 发生金额 | 占同类业 务比例 （％） | 本次预计金 额与上年实 际发生金额 差异较大的 | | --- | --- | --- | --- | --- | --- | --- | --- | | | | | | | | | 原因 | | 向关联人 | 贵州永 ...

一、拟聘任会计师事务所的基本情况 （一）机构信息 1.基本信息 名称：北京德皓国际会计师事务所（特殊普通合伙） 证券代码：603439 证券简称：贵州三力 公告编号：2025-019 贵州三力制药股份有限公司 关于续聘会计师事务所公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 拟聘任的会计师事务所名称：北京德皓国际会计师事务所（特殊普通合伙） （以下简称"北京德皓国际"）（曾用名：北京大华国际会计师事务所(特殊 普通合伙）） 贵州三力制药股份有限公司（以下简称"公司"）于 2025 年 4 月 21 日召开 第四届董事会第十二次会议，审议通过了《关于续聘会计师事务所的议案》，同 意续聘北京德皓国际会计师事务所（特殊普通合伙）为公司 2025 年度财务审计 机构和内部控制审计机构，本议案尚需提交公司股东大会审议，现将相关事项公 告如下： 成立日期：2008 年 12 月 8 日 组织形式：特殊普通合伙 注册地址：北京市西城区阜成门外大街 31 号 5 层 519A 首席合伙人：杨雄 截止 2024 年 12 ...